Human Epidermal Growth Factor Receptor 2 (HER2) Antibody Therapy with Lutetium-177 in Patients with Advanced Solid Tumours.
ACTRN 12625000191493 Brief Summary This study is evaluating the safety and properties…
Read more arrow_forwardACTRN 12625000191493 Brief Summary This study is evaluating the safety and properties…
Read more arrow_forwardACTRN 12619001768189 Brief Summary The aim of this clinical trial is to…
Read more arrow_forwardACTRN 12623000959673 Brief Summary This study is evaluating the safety and properties…
Read more arrow_forwardACTRN 12621001537842 Brief Summary This trial aims to determine whether NOX66 (idronoxil)…
Read more arrow_forwardACTRN 12623001216606 Brief Summary The purpose of the study is to investigate…
Read more arrow_forwardNCT 06736704 Brief Summary This study is testing a new medicine, SNV4818,…
Read more arrow_forwardNCT 06819735 Brief Summary This is a phase 1/2, dose-escalation and cohort-expansion…
Read more arrow_forwardNCT 07156136 Brief Summary Phase 1 First-in-human study of the safety and…
Read more arrow_forward